BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schoemaker MH, Rots MG, Beljaars L, Ypma AY, Jansen PL, Poelstra K, Moshage H, Haisma HJ. PDGF-receptor beta-targeted adenovirus redirects gene transfer from hepatocytes to activated stellate cells. Mol Pharm. 2008;5:399-406. [PMID: 18217712 DOI: 10.1021/mp700118p] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Salvati A, Poelstra K. Drug Targeting and Nanomedicine: Lessons Learned from Liver Targeting and Opportunities for Drug Innovation. Pharmaceutics 2022;14:217. [DOI: 10.3390/pharmaceutics14010217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wu L, Huang XQ, Li N, Xie C, Rao SX, Chen SY, Li F. A magnetic resonance imaging modality for non-invasively distinguishing progression of liver fibrosis by visualizing hepatic platelet-derived growth factor receptor-beta expression in mice. J Gastroenterol Hepatol 2021. [PMID: 34278598 DOI: 10.1111/jgh.15628] [Reference Citation Analysis]
3 Ma K, Tang D, Yu C, Zhao L. Progress in research on the roles of TGR5 receptor in liver diseases. Scand J Gastroenterol 2021;56:717-26. [PMID: 33771073 DOI: 10.1080/00365521.2021.1903547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chen Z, Jain A, Liu H, Zhao Z, Cheng K. Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis. J Pharmacol Exp Ther 2019;370:695-702. [PMID: 30886124 DOI: 10.1124/jpet.118.256156] [Cited by in Crossref: 16] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
5 Liu B, Saber A, Haisma HJ. CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment. Drug Discov Today 2019;24:955-70. [PMID: 30849442 DOI: 10.1016/j.drudis.2019.02.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
6 Li Q, Ding Y, Guo X, Luo S, Zhuang H, Zhou J, Xu N, Yan Z. Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo. J Cell Mol Med 2019;23:1951-62. [PMID: 30592139 DOI: 10.1111/jcmm.14097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
7 Abshagen K, Rotberg T, Genz B, Vollmar B. No significant impact of Foxf1 siRNA treatment in acute and chronic CCl4 liver injury. Exp Biol Med (Maywood) 2017;242:1389-97. [PMID: 28629226 DOI: 10.1177/1535370217716425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
8 Arabpour M, Cool RH, Faber KN, Quax WJ, Haisma HJ. Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells. J Drug Target 2017;25:360-9. [PMID: 27885847 DOI: 10.1080/1061186X.2016.1262867] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
9 Dobie R, Henderson NC. Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis. F1000Res 2016;5:F1000 Faculty Rev-1749. [PMID: 27508067 DOI: 10.12688/f1000research.8822.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
10 Thompson AI, Conroy KP, Henderson NC. Hepatic stellate cells: central modulators of hepatic carcinogenesis. BMC Gastroenterol. 2015;15:63. [PMID: 26013123 DOI: 10.1186/s12876-015-0291-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 8.3] [Reference Citation Analysis]
11 Poelstra K, Beljaars L, Melgert BN. Cell-specific delivery of biologicals: problems, pitfalls and possibilities of antifibrotic compounds in the liver. Drug Discovery Today 2013;18:1237-42. [DOI: 10.1016/j.drudis.2013.05.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
12 Reetz J, Genz B, Meier C, Kowtharapu BS, Timm F, Vollmar B, Herchenröder O, Abshagen K, Pützer BM. Development of Adenoviral Delivery Systems to Target Hepatic Stellate Cells In Vivo. PLoS One 2013;8:e67091. [PMID: 23825626 DOI: 10.1371/journal.pone.0067091] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
13 Li Q, Yan Z, Li F, Lu W, Wang J, Guo C. The improving effects on hepatic fibrosis of interferon-γ liposomes targeted to hepatic stellate cells. Nanotechnology. 2012;23:265101. [PMID: 22700686 DOI: 10.1088/0957-4484/23/26/265101] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
14 Li F, Li QH, Wang JY, Zhan CY, Xie C, Lu WY. Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor-beta on hepatic fibrosis in rats. J Control Release. 2012;159:261-270. [PMID: 22226772 DOI: 10.1016/j.jconrel.2011.12.023] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 4.4] [Reference Citation Analysis]
15 Bansal R, Prakash J, de Ruijter M, Beljaars L, Poelstra K. Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis. Mol Pharm 2011;8:1899-909. [PMID: 21800888 DOI: 10.1021/mp200263q] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
16 Raines SM, Richards OC, Schneider LR, Schueler KL, Rabaglia ME, Oler AT, Stapleton DS, Genové G, Dawson JA, Betsholtz C, Attie AD. Loss of PDGF-B activity increases hepatic vascular permeability and enhances insulin sensitivity. Am J Physiol Endocrinol Metab 2011;301:E517-26. [PMID: 21673305 DOI: 10.1152/ajpendo.00241.2011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
17 Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010;7:425-36. [DOI: 10.1038/nrgastro.2010.97] [Cited by in Crossref: 401] [Cited by in F6Publishing: 395] [Article Influence: 33.4] [Reference Citation Analysis]
18 Poelstra K, Greupink R, Beljaars L. Reprint of: Targeting fibrosis with selective drug carriers. Arab Journal of Gastroenterology 2010;11:63-5. [DOI: 10.1016/j.ajg.2010.05.001] [Reference Citation Analysis]
19 Prakash J, de Jong E, Post E, Gouw AS, Beljaars L, Poelstra K. A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier. J Control Release 2010;145:91-101. [PMID: 20362019 DOI: 10.1016/j.jconrel.2010.03.018] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
20 Haisma HJ, Kamps GK, Bouma A, Geel TM, Rots MG, Kariath A, Bellu AR. Selective targeting of adenovirus to alphavbeta3 integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies. Int J Pharm 2010;391:155-61. [PMID: 20211716 DOI: 10.1016/j.ijpharm.2010.02.032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
21 Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009;50:1294-306. [PMID: 19711424 DOI: 10.1002/hep.23123] [Cited by in Crossref: 220] [Cited by in F6Publishing: 225] [Article Influence: 16.9] [Reference Citation Analysis]
22 Soon RK, Yee HF. Stellate cell contraction: role, regulation, and potential therapeutic target. Clin Liver Dis. 2008;12:791-803, viii. [PMID: 18984467 DOI: 10.1016/j.cld.2008.07.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
23 Rosenbaum J. Vitamin A-guided siRNAs targeting a collagen chaperone can reverse experimental cirrhosis. J Hepatol 2008;49:1085-7. [PMID: 18950891 DOI: 10.1016/j.jhep.2008.09.009] [Reference Citation Analysis]
24 Zhao C, Dai CL. Role of Kupffer cells in hepatic fibrosis. Shijie Huaren Xiaohua Zazhi 2008; 16(26): 2959-2963 [DOI: 10.11569/wcjd.v16.i26.2959] [Reference Citation Analysis]